News | EP Lab | September 23, 2020

Boston Scientific Invests in Pulsed Field Ablation Technology To Improve Atrial Fibrillation Therapy

Deal with start-up Farapulse Inc. includes acquisition option to buy company

The Farapulse pulsed field ablation (PFA) system, also referred to as electroporation,  ablates heart tissue using the creation of an electric field instead of using thermal energy sources such as radiofrequency ablation or cryoablation.

The Farapulse pulsed field ablation (PFA) system ablates heart tissue using the creation of an electric field instead of using thermal energy sources such as radiofrequency ablation or cryoablation.
 

September 23, 2020 — Boston Scientific Corp. signed an investment agreement with an exclusive option to acquire Farapulse Inc., a privately-held company developing a pulsed field ablation (PFA) system for the treatment of atrial fibrillation (AF) and other cardiac arrhythmias. This PFA system – comprising a sheath, generator and catheters – is intended to ablate heart tissue via the creation of a therapeutic electric field instead of using thermal energy sources such as radiofrequency ablation or cryoablation.

Patients with AF, a common heart rhythm disorder that affects more than 33 million people globally, are often treated with anti-arrhythmic drugs as well as cardiac ablation.[1] Electrophysiology (EP) ablation therapy is the process of delivering energy to areas of the heart muscle responsible for creating an abnormal heart rhythm. The Farapulse platform employs an ablation modality based on pulsed electric fields, also referred to as irreversible electroporation, that generates zones of ablated cardiac tissue to interrupt the irregular electrical signals that can cause AF. This technology is designed for physicians to precisely ablate tissue and, in turn, spare nearby tissue from unintentional ablation.

"The tissue-selective Farapulse PFA technology is a promising energy source for cardiac ablation – including pulmonary vein isolation – with recent study results demonstrating the effectiveness of the ultra-rapid approach," said Allan Zingeler, president and chief executive officer of Farapulse. "This next chapter in our collaborative relationship with Boston Scientific will further accelerate our progress towards regulatory approval so we can bring this pioneering system to market."

Farapulse is pursuing regulatory approval in the U.S. and received FDA Breakthrough Designation for its endocardial ablation system in May 2019. The designation is intended to help patients receive more timely access to products that may provide a substantial improvement over existing therapies. The company intends to initiate a pivotal investigational device exemption (IDE) trial in the U.S. and is pursuing CE mark approval in Europe.  

"Our expanded investment in this technology, combined with our recent CE mrked cryo-ablation and contact force catheters with local impedance technology, affirms our commitment to offer physicians an innovative and comprehensive portfolio of electrophysiology products and services," said Scott Olson, senior vice president and president, rhythm management, Boston Scientific.

The Farapulse platform is an investigational device and not available for sale.

Pulsed field ablation is also referred to electroporation because its creates the opening of pores in the cell walls that lead to the destruction of the cell. Experts in EP ablation have said the technology has the potential for more efficient ablation compared to the current standards of heat or cold ablation technologies.

 

Related Pulse Electric Field Ablation Content:

First-in-human Electroporation Ablation Study Finds Pulsed Electric Fields Can Target Specific Tissue For Atrial Fibrillation

Pulsed AF Trial Shows Pulsed Field Ablation May be Safer Than Traditional RF Ablations

Medtronic FDA Trial Evaluates Pulsed Electric Fields to Treat Atrial Fibrillation

First Patients Treated with Galaxy Medical Centauri Pulsed Electric Field Cardiac Ablation System

 

Reference:

1. Chugh SS, et al. Worldwide epidemiology of atrial fibrillation: a global burden of disease 2010 study. Circulation 2014;129:837–847. doi: https://doi.org/10.1161/CIRCULATIONAHA.113.005119.

Related Content

The SERF VT EFS is a groundbreaking, single-arm observational study designed to evaluate the safety and effectiveness of the Thermedical Durablate catheter to treat VT. #HRS20 #HRS2020 #heartrhythm2020
News | Ablation Systems | May 08, 2020
May 8, 2020 – Results from a first-in-human early feasibility study (EFS) using a saline enhanced radiofrequency (SER
The Affera Inc. pulsed field (PF) energy radiofrequency ablation system. First-in-human trial shows new point-by-point approach provides increased flexibility and efficiency for physicians treating arrhythmia patients. #HRS #HRS2020 #HRS20 #heartrhythm20

The Affera Inc. pulsed field (PF) energy radiofrequency ablation system.

Feature | Ablation Systems | May 08, 2020
May 8, 2020 — A new clinical trial effectively uses pulsed field (PF) energy to treat patients with persistent or par
Noninvasive Radioablation Offers Long-term Benefits to High-risk Heart Arrhythmia Patients
News | Ablation Systems | September 17, 2019
September 17, 2019 — Treating high-risk heart patients with a single, high dose of radiation therapy can dramatically
Biosense Webster Announces Initial Results From First-in-Human QDOT-FAST Study
News | Ablation Systems | May 16, 2019
Johnson & Johnson Medical Devices Companies announced that Biosense Webster, Inc.’s QDot Micro catheter...
CardioFocus Announces Results From HeartLight X3 Ablation System Pivotal Study
News | Ablation Systems | May 16, 2019
CardioFocus Inc. announced the presentation of results from its pivotal confirmatory study evaluating the HeartLight X3...
New Global Consensus Statement Addresses Catheter Ablation of Ventricular Arrhythmias
News | Ablation Systems | May 14, 2019
The Heart Rhythm Society (HRS) in partnership with three other professional societies issued an international consensus...
Netherlands Hospital to Install State-of-the-Art MRI Ablation Center
News | Ablation Systems | May 13, 2019
Imricor announced the signing of a commercial agreement with the Haga Hospital in The Hague, Netherlands to outfit a...
A CyberHeart cardiac ablation radiotherapy treatment plan showing where the radiation beam will ablate for a noninvasive pulmonary vein isolation procedure. Varian acquires, buys, purchases Cyberheart.

A CyberHeart cardiac ablation radiotherapy treatment plan showing where the radiation beams will ablate for a noninvasive pulmonary vein isolation procedure to treat an arrhythmia.

Feature | Ablation Systems | May 10, 2019 | Dave Fornell, Editor
May 10, 2019 — Radiation oncology vendor Varian announced it acquired the start-up company CyberHeart, which has deve